CytRx Corporation (CYTR): Price and Financial Metrics


CytRx Corporation (CYTR)

Today's Latest Price: $0.72 USD

0.02 (-2.04%)

Updated Nov 27 8:28pm

Add CYTR to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

CYTR Stock Summary

  • Of note is the ratio of Cytrx Corp's sales and general administrative expense to its total operating expenses; 99.26% of US stocks have a lower such ratio.
  • For CYTR, its debt to operating expenses ratio is greater than that reported by only 0.39% of US equities we're observing.
  • With a year-over-year growth in debt of -100%, Cytrx Corp's debt growth rate surpasses just 0% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Cytrx Corp, a group of peers worth examining would be LOV, AMSC, AKRX, IPWR, and REGI.
  • CYTR's SEC filings can be seen here. And to visit Cytrx Corp's official web site, go to www.cytrx.com.

CYTR Stock Price Chart Interactive Chart >

Price chart for CYTR

CYTR Price/Volume Stats

Current price $0.72 52-week high $0.85
Prev. close $0.74 52-week low $0.23
Day low $0.70 Volume 39,000
Day high $0.75 Avg. volume 125,030
50-day MA $0.60 Dividend yield N/A
200-day MA $0.59 Market Cap 26.27M

CytRx Corporation (CYTR) Company Bio


CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company was founded in 1985 and is based in Los Angeles, California.


CYTR Latest News Stream


Event/Time News Detail
Loading, please wait...

CYTR Latest Social Stream


Loading social stream, please wait...

View Full CYTR Social Stream

Latest CYTR News From Around the Web

Below are the latest news stories about Cytrx Corp that investors may wish to consider to help them evaluate CYTR as an investment opportunity.

Arimoclomol application in U.S. fails to lift CytoRx

Thinly traded nano cap CytRx ([[CYTR]] -1.3%) is down out the gate this morning on the heels of its announcement that Orphazyme A/S has completed its rolling U.S. marketing application seeking approval of arimoclomol for the treatment of Niemann-Pick disease type-C, a rare inherited disorder characterized by the body's inability to...

Seeking Alpha | July 21, 2020

CytRx Corporation Highlights Orphazyme's Completion of Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S announced they have completed their rolling submission of their New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for arimoclomol for the treatment of Niemann-Pick Disease Type-C (NPC).

Yahoo | July 21, 2020

CytRx Corporation Highlights Orphazyme's Announcement of its Collaboration with The Michael J. Fox Foundation on Parkinson's Disease Research

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphazyme A/S announced it will join The Michael J. Fox Foundation's (MJFF) Parkinson's Disease Research Tools Consortium. The group brings together experts from the medical community and industry to identify and develop new pre-clinical tools to address unmet research needs and accelerate experiments. Orphazyme's drug candidate arimoclomol has potential across a range of neurodegenerative diseases, including GCase-deficient Parkinson's disease (PD).

Yahoo | July 20, 2020

CytRx up ~4% as Orphazyme reports positive outcome from mid-stage study of Arimoclomol in Gaucher Disease

CytRx ([[CYTR]] +4.3%) highlights that Orphayzme announces topline results of Phase 2 dose-finding study with arimoclomol in Gaucher disease (buildup of certain fatty substances in certain organs); In 2011, CytRx sold the rights to arimoclomol to Orphazyme.Orphazyme reported that arimoclomol demonstrated a relative reduction in serum chitotriosidase (Gaucher Disease Biomarker) from baseline to...

Seeking Alpha | June 29, 2020

CytRx Corporation Highlights Orphazyme's Announcement of its Phase 2 Study Results with Arimoclomol in Gaucher Disease

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S announced topline results of their Phase 2 dose-finding study with arimoclomol in Gaucher disease. The data showed a dose-dependent effect of arimoclomol on certain disease-relevant clinical secondary endpoints, such as liver and spleen size. Furthermore, the data demonstrated sustained levels of arimoclomol in the cerebrospinal fluid (CSF), providing further evidence of arimoclomol's ability to cross the brain-blood barrier.

Yahoo | June 29, 2020

Read More 'CYTR' Stories Here

CYTR Price Returns

1-mo 28.57%
3-mo 24.07%
6-mo -6.38%
1-year 148.28%
3-year -66.97%
5-year -96.17%
YTD 148.28%
2019 -35.56%
2018 -73.37%
2017 -23.87%
2016 -86.04%
2015 -3.28%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8485 seconds.